Novavax (NVAX): BTIG Recommends Buy with a Price Target of $19 - Pricing Power and Partnership With Sanofi are Impressing the Experts

Novavax Inc. (NVAX) is a biotechnology company focused on the development and commercialization of innovative vaccines for the prevention of severe infectious diseases. The company utilizes a proprietary protein vaccine platform and the Matrix-M adjuvant to achieve effective immune responses. Novavax gained recognition through its COVID-19 vaccine Nuvaxovid, a protein-based vaccine that serves as an alternative to mRNA-based vaccines. In addition to COVID-19, Novavax is working on vaccine candidates against other infectious diseases such as influenza,...